on GENFIT (EPA:GNFT)
GENFIT Publishes its 2024 Annual Reports
GENFIT, a biopharmaceutical company specializing in rare liver diseases, announced on April 29, 2025 the availability of its Universal Registration Document and its Annual Report on Form 20-F for the fiscal year 2024. These documents have been filed with the Autorité des Marchés Financiers (AMF) and the Securities and Exchange Commission (SEC), respectively.
The Universal Registration Document includes various reports, such as the annual financial report and the management report. The public can access these documents via GENFIT's website and those of the relevant regulators.
Access to this financial information is part of the company's ongoing transparency efforts, listed on Nasdaq and Euronext.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENFIT news